Skip to main content

Table 1 Population’s general characteristics and risk factors for IAI by pathogens sensitive to ATB 1 or to ATB 2

From: Intra-abdominal infections: the role of different classifications on the selection of the best antibiotic treatment

 TotalIAI by pathogens susceptible to ATB 1p valueIAI by pathogens susceptible to ATB 2p value
Age ≥ 70, n (%)101 (66)52 (65)0.87472 (64)0.253
Male gender, n (%)74 (48)46 (58)0.01549 (47)0.614
Karnofsky Performance Status Scale < 70, n (%)112 (73)62 (78)0.16773 (70)0.191
Diabetes, n (%)45 (29)19 (24)0.12128 (27)0.308
Liver disease, n (%)14 (9)6 (8)0.4756 (6)0.033
Solid tumour, n (%)45 (29)23 (29)0.89431 (30)0.904
AIDS, n (%)1 (1)1 (1)1.000a1 (1)1.000a
Chronic kidney disease, n (%)26 (17)9 (11)0.05218 (17)0.900
Congestive heart failure, n (%)11 (7)7 (9)0.537a8 (8)1.000a
Myocardial infarction, n (%)10 (7)7 (9)0.331a9 (9)0.171a
Chronic obstructive pulmonary disease, n (%)10 (7)6 (8)0.748a8 (8)0.504a
Peripheral vascular disease, n (%)22 (14)11 (14)0.84314 (13)0.621
Cerebrovascular accident/transient ischemic attack, n (%)14 (9)8 (10)0.68311 (11)0.550a
Dementia, n (%)11 (7)3 (4)0.120a7 (7)1.000a
Hemiplegia, n (%)1 (1)1 (1)1.000a1 (1)1.000a
Connective tissue disease, n (%)2 (1)1 (1)1.000a1 (1)1.000a
Leukemia, n (%)3 (2)1 (1)0.608a2 (2)1.000a
Malignant lymphoma, n (%)1 (1)1 (1)1.000a1 (1)1.000a
Peptic ulcer disease, n (%)4 (3)3 (4)0.621a3 (3)1.000a
Total score - Charlson Comorbidity Index, mean ± SD5 ± 35 ± 30.7445 ± 30.352
Residence in a long-term care facility or nursing home, n (%)7 (5)2 (3)0.259a4 (4)0.681a
Previous colonization/infection by DR pathogen, n (%)29 (19)16 (20)0.70020 (19)0.920
Previous antibiotic therapy, n (%)39 (25)14 (18)0.02022 (21)0.068
Previous hospitalization, n (%)82 (53)37 (46)0.07051 (49)0.089
Previous invasive procedures, n (%)78 (51)34 (43)0.02848 (46)0.082
Post-operative Infection, n (%)19 (12)9 (11)0.6709 (9)0.037
  1. aFisher’s exact test; AIDS, acquired immune deficiency syndrome; ATB 1, non-pseudomonal cephalosporin or ciprofloxacin plus metronidazole; ATB 2, piperacillin/tazobactam; DR drug-resistant, OR odds ratio, SD standard deviation